Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 4/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 5/20 | 0.31 |
| ▸ | GPR6 | P46095 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717259 | 0.84 | PDE4D (0.35) | — | |
| SCHEMBL23717463 | 0.81 | CASR (0.34) | — | |
| SCHEMBL24345431 | 0.78 | FPR2 (0.34) | FPR2PROKR1GPR6CD38 | |
| SCHEMBL23674935 | 0.76 | KMT2A (0.40) | FPR2PROKR1ACACBGPR6TYRO3 | |
| SCHEMBL23717496 | 0.74 | GLA (0.40) | GPR6TYRO3CD38 | |
| SCHEMBL20746863 | 0.72 | KDM4E (0.33) | — | |
| SCHEMBL17127789 | 0.72 | GABRA1 (0.36) | — | |
| SCHEMBL24345422 | 0.72 | HRH1 (0.44) | — | |
| SCHEMBL26762032 | 0.71 | CRHR1 (0.33) | — | |
| SCHEMBL26762030 | 0.71 | KMO (0.32) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | ALK 3169/4885FPR2 421/4885PROKR1 2760/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | ALK 3169/4885FPR2 421/4885PROKR1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.